Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib and Trastuzumab in HER2+ Metastatic Breast Cancer
NCT02066532Phase 2Completed
- Sponsor
- Dawn L. Hershman
- Start
- Jun 2014
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in HER2-positive metastatic breast cancer, sponsored by Dawn L. Hershman. Started Jun 2014; status: completed.
02
Drugs
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT02066532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02066532.